Webinar-Hopewell Site Capabilities In June 2025, ProBio CDMO, the biologics subsidiary of GenScript, expanded its plasmid DNA and viral vector production capacity with the opening of its flagship Cell and Gene Therapy Center of Excellence, at the Princeton West Innovation Campus in Hopewell, New Jersey. In April 2026, ProBio CDMO announced the release of its Viral Vector Packaging Test, a new early stage development offering designed to accelerate decision making and de risk progression from discovery to CMC in cell and gene therapy programs. The launch builds on the opening of ProBio’s state of the art viral vector facility, further strengthening the company’s end to end capabilities in advanced therapies. Join Lance Marquardt, Director of Manufacturing Operations, on a showcase of our GMP Manufacturing facilities and highlights of our PD and IND services. Lance MarquardtDirector of Manufacturing OperationsHopewell,New Jersey Watch now « Previous Page ProBio Announces New Executive Appointments Next Page ProBio Accelerates Chimagen's Global Market Expansion, Paving the Way for Innovative Antibody Therapy » Contact us Phone: 1-877-436-7274 (Toll-Free); 1-732-885-9188 Fax: 1-732-210-0262
Latest WebinarsWebinar-Hopewell Site CapabilitiesWebinar – Integrated mRNA & circRNA-tLNP Platform Empowering In Vivo CAR-T TherapiesIn Vivo CAR T Made Real: Overcoming CMC BarriersIn Vivo CAR-T Webinar | Industrialization of In Vivo CAR-T Therapy Development | ProBio CDMOFind More Cell & Gene Therapy Categories